Merck KGaA: This time we’ve got our R&D act together (seriously)
Merck KGaA has one of the worst R&D track records of any biopharma company of its size. Its life sciences group has gone well over a decade without any major new drug approvals. It’s experienced a series of painful and often predictable setbacks in the clinic. And every time it’s promised rapid development progress in recent years, it’s had to back off the pledge.
But this time, the German company insists, they’ve got it down.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.